If you follow aesthetic treatments online, you may have encountered Skinvive, Profhilo, Juvéderm Volite, or Restylane Skinboosters. They are often discussed together as treatments for hydrated, smoother-looking skin.
However, “skin booster” is a broad description, not a guarantee that products share the same formulation, approved uses, or supporting evidence.
Start with the exact product
Injectable hyaluronic acid products can differ in concentration, modification, physical properties, intended tissue placement, and treatment schedule.
Those differences influence how a product behaves and what it is designed to accomplish. A familiar ingredient does not make two products interchangeable.
Even products within the same brand family can have different indications and instructions.
What is Skinvive approved to do?
In the United States, Skinvive by Juvéderm is FDA-approved to improve cheek skin smoothness and reduce neck lines for improvement of neck appearance in adults over age 21. The neck indication was added in June 2026.
In cheek-treatment studies, participants also reported satisfaction with how hydrated, radiant, refreshed, and healthy their skin looked. Results lasted six months with optimal treatment. Neck treatment has its own evidence, technique, and expected outcomes.
These approvals do not establish that Skinvive treats significant skin laxity, deep acne scars, or every facial or body area.
What about products discussed internationally?
You may see Profhilo, Juvéderm Volite, and Restylane Skinboosters discussed by practitioners outside the United States.
A product’s availability or regulatory status in another country does not establish FDA approval. Likewise, a CE mark is not the same as FDA approval.
Names, labeling, treatment protocols, and available formulations can differ between markets. International recommendations should not be copied into a US treatment plan without checking the exact product and its applicable labeling.
Are they all collagen stimulators?
Not in the same sense, and the term should not be used indiscriminately.
Claims about collagen production, elasticity, hydration, and lifting need evidence for the specific product and treatment method. Laboratory findings do not automatically prove a visible tightening effect in patients.
For Skinvive, cheek smoothness is the approved indication. Patient-reported improvements should be described accurately rather than expanded into promises about structural lifting or facial rejuvenation.
Can results or schedules be compared directly?
A treatment lasting six months in one study cannot automatically be compared with a different product studied using another protocol or outcome measure.
The number of sessions, amount used, maintenance schedule, and recovery should follow the selected product and individual treatment plan. There is no universal skin-booster schedule.
What should you ask your provider?
Ask for the exact product name, its regulatory status, the proposed treatment area, and the evidence supporting the recommendation.
You should also understand expected recovery, important risks, alternatives, and total cost. These are injectable medical treatments, including the potential for uncommon but serious vascular complications.
At Modern Aesthetics in San Jose, I focus on whether a product addresses your concern and fits an appropriate treatment plan. Schedule a consultation to discuss your skin goals and the options available to you.
Updated October 23, 2026.